Literature DB >> 8764029

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes.

R Hanecak1, V Brown-Driver, M C Fox, R F Azad, S Furusako, C Nozaki, C Ford, H Sasmor, K P Anderson.   

Abstract

Genetic and biochemical studies have provided convincing evidence that the 5' noncoding region (5' NCR) of hepatitis C virus (HCV) is highly conserved among viral isolates worldwide and that translation of HCV is directed by an internal ribosome entry site (IRES) located within the 5' NCR. We have investigated inhibition of HCV gene expression using antisense oligonucleotides complementary to the 5' NCR, translation initiation codon, and core protein coding sequences. Oligonucleotides were evaluated for activity after treatment of a human hepatocyte cell line expressing the HCV 5' NCR, core protein coding sequences, and the majority of the envelope gene (E1). More than 50 oligonucleotides were evaluated for inhibition of HCV RNA and protein expression. Two oligonucleotides, ISIS 6095, targeted to a stem-loop structure within the 5' NCR known to be important for IRES function, and ISIS 6547, targeted to sequences spanning the AUG used for initiation of HCV polyprotein translation, were found to be the most effective at inhibiting HCV gene expression. ISIS 6095 and 6547 caused concentration-dependent reductions in HCV RNA and protein levels, with 50% inhibitory concentrations of 0.1 to 0.2 microM. Reduction of RNA levels, and subsequently protein levels, by these phosphorothioate oligonucleotides was consistent with RNase H cleavage of RNA at the site of oligonucleotide hybridization. Chemically modified HCV antisense phosphodiester oligonucleotides were designed and evaluated for inhibition of core protein expression to identify oligonucleotides and HCV target sequences that do not require RNase H activity to inhibit expression. A uniformly modified 2'-methoxyethoxy phosphodiester antisense oligonucleotide complementary to the initiator AUG reduced HCV core protein levels as effectively as phosphorothioate oligonucleotide ISIS 6095 but without reducing HCV RNA levels. Results of our studies show that HCV gene expression is reduced by antisense oligonucleotides and demonstrate that it is feasible to design antisense oligonucleotide inhibitors of translation that do not require RNase H activation. The data demonstrate that chemically modified antisense oligonucleotides can be used as tools to identify important regulatory sequences and/or structures important for efficient translation of HCV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764029      PMCID: PMC190476     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Anatomy of the poliovirus internal ribosome entry site.

Authors:  E Ehrenfeld; B L Semler
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

Review 3.  Progress in antisense therapeutics.

Authors:  S T Crooke
Journal:  Hematol Pathol       Date:  1995

4.  Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides.

Authors:  M Alt; R Renz; P H Hofschneider; G Paumgartner; W H Caselmann
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

5.  Inhibition of vesicular stomatitis virus protein synthesis and infection by sequence-specific oligodeoxyribonucleoside methylphosphonates.

Authors:  C H Agris; K R Blake; P S Miller; M P Reddy; P O Ts'o
Journal:  Biochemistry       Date:  1986-10-07       Impact factor: 3.162

6.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity.

Authors:  L L Cummins; S R Owens; L M Risen; E A Lesnik; S M Freier; D McGee; C J Guinosso; P D Cook
Journal:  Nucleic Acids Res       Date:  1995-06-11       Impact factor: 16.971

7.  Mapping the 5' and 3' ends of Tetrahymena thermophila mRNAs using RNA ligase mediated amplification of cDNA ends (RLM-RACE).

Authors:  X Liu; M A Gorovsky
Journal:  Nucleic Acids Res       Date:  1993-10-25       Impact factor: 16.971

8.  A conserved helical element is essential for internal initiation of translation of hepatitis C virus RNA.

Authors:  C Wang; P Sarnow; A Siddiqui
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.

Authors:  N M Dean; R McKay; T P Condon; C F Bennett
Journal:  J Biol Chem       Date:  1994-06-10       Impact factor: 5.157

10.  An RNA pseudoknot is an essential structural element of the internal ribosome entry site located within the hepatitis C virus 5' noncoding region.

Authors:  C Wang; S Y Le; N Ali; A Siddiqui
Journal:  RNA       Date:  1995-07       Impact factor: 4.942

View more
  25 in total

Review 1.  Translational control of viral gene expression in eukaryotes.

Authors:  M Gale; S L Tan; M G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2000-06       Impact factor: 11.056

2.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

Review 4.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.

Authors:  K P Anderson; M C Fox; V Brown-Driver; M J Martin; R F Azad
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

7.  Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.

Authors:  Partha K Chandra; Sidhartha Hazari; Bret Poat; Feyza Gunduz; Ramesh Prabhu; Gerald Liu; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Virol J       Date:  2010-06-07       Impact factor: 4.099

8.  Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs).

Authors:  Christopher J Nulf; David Corey
Journal:  Nucleic Acids Res       Date:  2004-07-19       Impact factor: 16.971

9.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 10.  Novel therapies in hepatitis B and C.

Authors:  Bart Takkenberg; Joep de Bruijne; Christine Weegink; Peter Jansen; Hendrik Reesink
Journal:  Curr Gastroenterol Rep       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.